IFNã-neutralizing peptides to treat Amyotrophic Lateral Sclerosis (Feasibility study)

• Research unit: INNOSUISSE
• Project number: 14340.1;7 PFLS-LS

Short description (English)

IFNã-neutralizing peptides to treat Amyotrophic Lateral Sclerosis (Feasibility study)

Short description (French)

IFNy-neutralizing peptides to treat Amyotrophic Lateral Sclerosis (Feasibility study)

Abstract (English)

The proposed feasibility study concerns the development of a novel synthetic drug for Amyotrophic Lateral Sclerosis and Parkinson disease. Lascco¿s program on neurodegenerative diseases targets IFNã-mediated death pathways and neuroinflammation. This study aims at providing critical data on the identification and selection of small peptides with high affinity, stability, and biocompatibility, and with the unique ability to induce IFNã neutralization. The two best hit compounds will then, in a subsequent phase, be integrated in polymer delivery platforms and evaluated in vivo

Abstract (French)

The proposed feasibility study concerns the development of a novel synthetic drug for Amyotrophic Lateral Sclerosis and Parkinson disease. Lascco¿s program on neurodegenerative diseases targets IFNã-mediated death pathways and neuroinflammation. This study aims at providing critical data on the identification and selection of small peptides with high affinity, stability, and biocompatibility, and with the unique ability to induce IFNã neutralization. The two best hit compounds will then, in a subsequent phase, be integrated in polymer delivery platforms and evaluated in vivo